Walvax Biotechnology Co., Ltd.

SZSE:300142 주식 보고서

시가총액: CN¥23.2b

Walvax Biotechnology 과거 수익 실적

과거 기준 확인 0/6

Walvax Biotechnology's earnings have been declining at an average annual rate of -10.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 19.3% per year. Walvax Biotechnology's return on equity is 1.4%, and it has net margins of 4%.

주요 정보

-10.6%

수익 성장률

-11.6%

EPS 성장률

Biotechs 산업 성장11.3%
매출 성장률19.3%
자기자본 수익률1.4%
순이익4.0%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07
There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Recent updates

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Sep 24
Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23
Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07
There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02
Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

수익 및 비용 분석

Walvax Biotechnology 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SZSE:300142 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 243,0971221,337621
30 Jun 243,3791351,597687
31 Mar 243,8802621,787672
31 Dec 234,1144191,868763
30 Sep 234,5387512,025818
30 Jun 234,9067632,206885
31 Mar 235,2648622,353962
01 Jan 235,0867292,301922
30 Sep 225,0405952,320958
30 Jun 224,4615302,011827
31 Mar 223,6854341,729704
01 Jan 223,4634281,631616
30 Sep 213,5019321,575355
30 Jun 213,7151,2611,670311
31 Mar 213,2601,0531,473212
31 Dec 202,9391,0031,345174
30 Sep 201,8904571,000174
30 Jun 201,19411969982
31 Mar 201,0578568562
31 Dec 191,12114266063
30 Sep 191,0981,44455775
30 Jun 191,0001,42654195
31 Mar 199331,430412135
31 Dec 188741,415418138
30 Sep 18807-407504127
30 Jun 18786-421399166
31 Mar 18700-484432111
31 Dec 17668-53743994
30 Sep 1762826527672
30 Jun 175551893450
31 Mar 17466833580
31 Dec 16591703750
30 Sep 16692-9636410
30 Jun 16885-9366590
31 Mar 161,045-8356220
31 Dec 151,006-8416240
30 Sep 158431825270
30 Jun 157311385570
31 Mar 157051475500
31 Dec 147191435540
30 Sep 14816-1394690
30 Jun 14750-914330
31 Mar 14676-293910
31 Dec 13583483550

양질의 수익: 300142 has a large one-off loss of CN¥120.5M impacting its last 12 months of financial results to 30th September, 2024.

이익 마진 증가: 300142's current net profit margins (4%) are lower than last year (16.5%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 300142's earnings have declined by 10.6% per year over the past 5 years.

성장 가속화: 300142's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

수익 대 산업: 300142 had negative earnings growth (-83.7%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).


자기자본 수익률

높은 ROE: 300142's Return on Equity (1.4%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기